Qtrex Quantum Ltd. · NASDAQ:QTEX

Qtrex Quantum — Inspira Technologies OXY B.H.N. — Investor Presentation (February 2022)

48 slides from Qtrex Quantum's investor presentation, Feb 1, 2022

Slide 1: Revolutionizing Acute Respiratory Care
Revolutionizing Acute Respiratory Care February 2022 Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved Nasdaq: IINN / IINNW
Slide 2: Forward Looking Statements
2 Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved Forward looking - Statements This presentation of Inspira TM Technologies Oxy B.H.N. Ltd. (Inspira Technologies or the “Company”) contains “forward - looking statements” within the meaning of the Private Securities L
Slide 3: Investment Highlights
Investment Highlights Targeted medical Device companies Forecasting growth The potential market for the company is expected to grow steadily in the coming years due to the increasing prevalence of chronic disorders, growing geriatric population which is typically at high risk of acute respiratory fa
Slide 4: Inspira – Capital Raising Pathway
Inspira – Capital Raising Pathway Company i n co rp o r a t i on $12 million Have raised by the company prior to IPO $16 million Raised at initial public offering on NASDAQ $26 million On - hand cash, including $9.4 million through investors exercising 1.7m warrants at $5.50 per share Feb.2018 2019
Slide 5: Vision: Redefining Artificial Respiration
Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved Vision Redefining Artificial Respiration to impact millions of lives 5
Slide 6: Our mission: alternative to invasive mechanical ventilation
Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved 6 Our mission is to provide an alternative to invasive mechanical ventilation for acute respiratory patients who continue to deteriorate while being treated with non - invasive ventilation treatment. ▪ Non - invasive v
Slide 7: Respiratory Failure: The Unmet Need
Respiratory Failure The Unmet Need
Slide 8: Respiratory Failure - Definition
Respiratory Failure - Definition Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved Respiratory failure is a serious medical condition that develops when the lungs cannot get sufficient oxygen into the blood. Buildup of carbon dioxide can also damage the tissues and or
Slide 9: Mechanical ventilation risks and complications
1. Am J Respir Crit Care Med Vol. 196, P3 - 4, 2017. ATS Patient Education Series © 2017 American Thoracic Society 2. Diling Wu et al. Frontiers in pharmacology MINI REVIEW published: 09 May 2019. doi: 10.3389/fphar.2019.00482 3. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hos
Slide 10: Acute Respiratory Failure: Current Treatment Paradigm
Acute Respiratory Failure: Current Treatment Paradigm Acute Respiratory Failure Hypercarbia H y p o x em ia RESPIRATORY DETERIORATION • N asal m ask • F a c e m a sk • N a s a l p l u g s • B I P AP C P AP Non - Invasive Ventilation¹ ECMO³ Extracorporeal Membrane Oxygenation • Oxygen Helmet • HFNC (
Slide 11: Inspira developing minimally invasive extracorporeal blood oxygenation system
Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved Inspira Technologies is developing a minimally invasive, cost - effective early - stage extracorporeal blood oxygenation system that utilizes a proprietary hemo - protective flow technology to rebalance oxygen saturati
Slide 12: Market Potential
Market Potential • The U.S. Market • Multiple trends propelling the market • COVID - 19 and growing medical community experience with extracorporeal respiratory systems is expected to accelerate market adoption
Slide 13: Potential Market Size in the U.S. (Primary Market)
Potential Market Size in the U.S. (Primary Market) Etiologies: ARDS, Pneumonia, Sepsis, COPD and acute Asthma patients 1. Kempker, Jordan A. MD, MSc et al. “The Epidemiology of Respiratory Failure in the United States 2002 – 2017: A Serial Cross - Sectional Study”. Critical Care Explorations: June 2
Slide 14: Multiple Trends Propelling the Market in the Coming Years
Multiple Trends Propelling the Market in the Coming Years Growing geriatric population According to estimates published by the WHO, the global population aged 60 years and above is expected to increase to 2 billion by 2050 1. R.Torres - Castro et al. “Respiratory function in patients post - infectio
Slide 15: Medical Community Experience with ECMO Following COVID-19
Experience Gained by the Medical Community with ECMO Following COVID - 19 May Potentially Facilitate Faster Adoption of ART TM In the last 5 years, 26,582 adults with pulmonary diseases were treated with VV - ECMO (international data) as a last resort treatment¹ ECMO = extracorporeal membrane oxygen
Slide 17: Inspira's ART System
Inspira’s ART TM System * Awake Patient Cannula Insertion Hemo - protective extracorporeal treatment Discharge Mechanical Ventilation IV sedation Intubation Artificial Respiration Ventilator Associated Complications Weaning Discharge *These photos are for illustration purposes only. The Company’s pr
Slide 18: Extracorporeal approach
Extracorporeal approach A system specifically designed to provide continuous low - flow venous - venous early - stage extracorporeal respiratory support Cannula is designed to draw blood at a rate of 1 - 1.5L per minute¹ Rebalancing oxygenation saturation levels & CO2 removal O2 saturation level is
Slide 19: ART Treatment - Possible Indications
ART Ƞ Treatment - Possible Indications ART TM may be used for the treatment of acute respiratory failure patients suffering from hypoxemia and hypercarbia or both, who continue to deteriorate while being treated with non - invasive ventilation treatment. A cute R espiratory D istress S yndrome Pn eu
Slide 20: The ART Device: How does it work?
INSERT Dual lumen cannula inserted into the jugular vein WITHDRAW Utilizing hemo - protective flow technology, the blood is treated with a minimum drop in blood pressure & a low sheer force, protecting the red blood cells Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reser
Slide 21: The ART – Hemo Protective System
Oxygenator Initiation System Pump THE ART TM – Hemo Protective System T h e A R T S y s t e m i s a m edi c a l d e vic e includin g a r eplace a bl e di s p os abl e r e s pi r a t o r y s upp o r t uni t (ki t ) f o r e a c h p a t ie n t t r e a t me n t. T h e A R T ’ s de s i g n s upp o r t s
Slide 22: ART System Primary Components
Dual Lumen Cannula He m o - P r o t ec t ive Flow Pump Component : Proprietary hemo - protective pump; designed to prevent hemolysis and thrombosis Initiation System ART Ρ System Primary Components Component : Dual lumen cannula, with small diameter (16 - 21Fr*) designed to draw blood at a rate of 1
Slide 23: Disposable Respiratory Support Unit and Control Unit
Disposable Respiratory Support Unit (kit) Component : Plug - and - play disposable cartridge. suitable for deployment in both in ICUs and in general medical unit settings ART Ρ System Primary Components Control unit Component : An algorithm enhanced digital platform, controls and displays all sensor
Slide 24: ART's Innovative Features
ART ’s Innovative Features Hemo - protective flow technology aimed to reduce the risks of hemolysis & thrombosis Single insertion point of dual - lumen cannula will potentially be lowering the risk of multiple infections & bleeding Proprietary plug - and - play replaceable disposable unit expected t
Slide 25: ART's Proprietary Hemo-Protective Flow Technology
Copyright © 2018 - 2021 Inspira Technologies OXY B.H.N. LTD., All rights reserved 25 A R T ’ s P r o p r i e t a r y H e m o - P r o t e ct i v e F l o w T ec h nolo g y F e a t u r es Bloo d p r o t e ct ion 1 - 1.5 liters of blood are being enriched with oxygen, rebalance patient’s oxygen saturati
Slide 26: ART Respiratory Support System Potential Benefits
Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved ART's Respiratory Support System Potential Benefits The patient's perspective • Immediate oxygen saturation elevation • No need for induced coma • Decreased work of breathing - Improving compliance to High Flow Nasal C
Slide 27: ART System Offers Two Intervention Modalities
Co p y r i g ht © 2018 - 2 0 2 2 I nsp i ra Te chn o l og i e s O XY B. H . N. LT D . , A l l r i g hts r ese rv e d 27 ART TM System Offers Two Intervention Modalities 1. 2. Prevent mechanical ventilation Avoid, VILI (Ventilator - induced lung injury) ,VIDD ( Ventilator induced diaphragmatic dysfun
Slide 28: What Differentiates ART from ECMO?
ART TM System What Differentiates ART from ECMO? ECMO is a salvage therapy There is no “plan B ”when a patient is not improving with ECMO Two single lumen cannulas - Typically, two large (21 - 25 fr) single lumen cannulas are used to withdraw and return 5 - 7 liters of blood per minute Patients are
Slide 29: Pre-Clinical Studies (In-vivo)
Pre - Clinical Studies (In - vivo)
Slide 30: Studies Results Highlights
Studies Results Highlights ART treatment in hypoxemic swine model, resulted in significant increase of oxygen saturation by 8% - 10% A flow of 1 liter per minute, was sufficient to provide a saturation increase of 8 - 10% Pulmonary artery saturation increase is attributed to ART device activity. Doc
Slide 31: Pre-clinical Studies (In-vivo)
Pre - clinical Studies (In - vivo) 1. Research protocol was approved by the national ethics committee of animal experimentations. 2. LAHAV CRO https://lahavcro.com/ 3. ART Treatment = extracorporeal blood oxygenation with one liter of blood Additional studies were conducted • During 2019 - 2020, add
Slide 32: Pre-clinical study method and swine model
In these initial pre - clinical studies the goal was to assess the oxygenation effectiveness of ART system¹ in swine model. M e th o d Sw i n e mo d e l The swine species chosen for the current study is Large - White X Landrace. This breed was chosen due to a well - known resemblance of the anatomy,
Slide 33: Study design
Study design Blood oxygenation and CO2 removal at a flow rate of 1 liter/min was assessed in 20 consecutive observations , with each test, the following steps were repeated: Blood samples are taken from the (1) femoral vein (2) pulmonary artery, and (3) carotid artery at baseline (prior to the activ
Slide 35: ART Provides Significant Increase In Saturation
ART Provides Significant Increase In Saturation The saturation levels in the pulmonary artery increased on average by 26%, and in the carotid artery by about 8 - 10% 0.48 0.72 0.93 1.00 0.90 0.80 0.70 0.60 0.50 0.40 0.30 0.20 0.10 0.00 Femoral vein Pulmonary artery Carotid artery ART oxygenation Lun
Slide 36: ART's Contribution to Oxygen Saturation
1.00 0.90 0.80 0.70 0.60 0.50 0.40 0.30 0.20 0.10 0.00 SvO2 & SaO2 0.37 0.48 0.46 0.72 0.85 0.93 OFF Femoral vein ON Femoral vein OFF P ul m o n a r y artery ON P ul m o n a r y artery OFF Carotid artery ON Carotid artery Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reser
Slide 37: CO2 Removal Via ART Is Significant
CO2 Removal Via ART Is Significant 40.53 36.74 38.33 29.83 33.5 27.75 OFF Femoral vein ON Femoral vein OFF P ul m o n a r y artery ON P ul m o n a r y artery OFF Carotid artery ON Carotid artery Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved 45.00 40.00 35.00 30.00
Slide 38: Go To Market
INFO Go To Market
Slide 39: Inspira's Product Pipeline
Inspira’s Product Pipeline ECLS system Intended use: Extracorporeal Life Support, last resort treatment Flow rate: will be used to withdraw and return 5 - 7 liters of blood per minute, all patient’s cardiac output Treatment setting: Intensive Care Unit ART System Intended use: Extracorporeal Respira
Slide 40: Go-to-Market Strategy
Go - to - Market Strategy Establishing multiple recurring revenue streams across medical sectors & markets Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved P u r s u i n g r e g u l a t o r y ap p r o v a l s in key markets: United States – Primary market Europe – Se
Slide 41: Market Penetration and Gaining Market Share
Market Penetration and Gaining Market Share We have developed a flexible business model to drive global deployment PRICING MODEL ART system distributed as an OPEX when bundled with disposable respiratory support kits Novel technology ART system Disposable respiratory support kits + Healthcare Center
Slide 42: Reimbursement Strategy
Reimbursement Strategy Inspira plans to utilize existing CPT Codes using a “New Approach” to an existing procedure Expected to eliminate complications associated with MV Aimed to reduce length of stay & re - admissions Designed to reduced costs & operational expenses Designed to reduce hospital & st
Slide 43: Regulatory Submission (Multi-Step approach)
H1 - 2022 H1 - 2023 H2 - 2023 H2 - 2024 Class II 510(k) submission of the ECLS Regulatory filing for de - novo or PMA for the multi - function sources of ART in the US Submission of an application for the CE Mark Listing the first Class I 510(k) (exempt) relating to component of the ART Regulatory S
Slide 44: Targeting Major Milestones 2022-2023
Targeting Major Milestones 2022 - 2023 H1 - 2022 Strategic distribution agreement FDA listing of ART component Strategic agreement COMPONENT H2 - 2022 D is t ribu t i o n Agr ee m e n t Medical collaboration Regulatory Filings Distribution Agreement Strategic Agreement Product Deployment Medical Col
Slide 45: Leadership
Lea d e r s h ip Urologic surgeon, inventor, entrepreneur & venture capital investor. Vast experience in leading high growth, publicly traded medical companies . Co - founded Vidamed Inc., acquired by Medtronic Inc. (NYSE: MDT). Co - founded Medinol, partnered with Boston Scientific (NYSE: BSX). For
Slide 46: Scientific Advisory Board
Scientific Advisory Board Cardiac Surgeon & Director of ECMO Israel, Adult Cardiac Surgery, Heart Transplants, Assist Devices & ECMO, Intensive Care Treatment, Sheba Medical Center at Sheba Hospital. Cambridge University, UCLA, Hebrew University of Jerusalem, Cardiac surgery clinical fellowship in U
Slide 47: Scientific Advisory Board - cont.
Scientific Advisory Board - cont. A director of the Medical ICU at Sourasky Medical Center since 2020 and is also Treasurer of the Israeli ECMO Society since 2019. Dr. Lichter completed her residency programs in Internal Medicine (2015) and Intensive Care (2017) at the Sourasky Medical Center. Prior

Inspira Technologies OXY B.H.N. — Investor Presentation (February 2022) on 6ix

Qtrex Quantum — Inspira Technologies OXY B.H.N. — Investor Presentation (February 2022)

Slide 1: Revolutionizing Acute Respiratory Care

Slide 2: Forward Looking Statements

Slide 3: Investment Highlights

Slide 4: Inspira – Capital Raising Pathway

Slide 5: Vision: Redefining Artificial Respiration

Slide 6: Our mission: alternative to invasive mechanical ventilation

Slide 7: Respiratory Failure: The Unmet Need

Slide 8: Respiratory Failure - Definition

Slide 9: Mechanical ventilation risks and complications

Slide 10: Acute Respiratory Failure: Current Treatment Paradigm

Slide 11: Inspira developing minimally invasive extracorporeal blood oxygenation system

Slide 12: Market Potential

Slide 13: Potential Market Size in the U.S. (Primary Market)

Slide 14: Multiple Trends Propelling the Market in the Coming Years

Slide 15: Medical Community Experience with ECMO Following COVID-19

Slide 16: Respiratory Support

Slide 17: Inspira's ART System

Slide 18: Extracorporeal approach

Slide 19: ART Treatment - Possible Indications

Slide 20: The ART Device: How does it work?

Slide 21: The ART – Hemo Protective System

Slide 22: ART System Primary Components

Slide 23: Disposable Respiratory Support Unit and Control Unit

Slide 24: ART's Innovative Features

Slide 25: ART's Proprietary Hemo-Protective Flow Technology

Slide 26: ART Respiratory Support System Potential Benefits

Slide 27: ART System Offers Two Intervention Modalities

Slide 28: What Differentiates ART from ECMO?

Slide 29: Pre-Clinical Studies (In-vivo)

Slide 30: Studies Results Highlights

Slide 31: Pre-clinical Studies (In-vivo)

Slide 32: Pre-clinical study method and swine model

Slide 33: Study design

Slide 34: Study Results

Slide 35: ART Provides Significant Increase In Saturation

Slide 36: ART's Contribution to Oxygen Saturation

Slide 37: CO2 Removal Via ART Is Significant

Slide 38: Go To Market

Slide 39: Inspira's Product Pipeline

Slide 40: Go-to-Market Strategy

Slide 41: Market Penetration and Gaining Market Share

Slide 42: Reimbursement Strategy

Slide 43: Regulatory Submission (Multi-Step approach)

Slide 44: Targeting Major Milestones 2022-2023

Slide 45: Leadership

Slide 46: Scientific Advisory Board

Slide 47: Scientific Advisory Board - cont.

Slide 48: Thank You